SEEK seeks partners and funding as Phase III HIV-v vaccine shows high one-shot efficacy
This article was originally published in Scrip
Executive Summary
Privately owned biopharmaceutical company, SEEK, is planning for the final stages of development of its HIV-v vaccine, after announcing that the product has demonstrated proof of efficacy in a Phase Ib/II study.